Responses
Therapeutics/Prevention
Randomised controlled trial
SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease
Compose a Response to This Article
Other responses
No responses have been published for this article.